Related Experiment Video
Updated: May 8, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Case Report: Safety and efficacy assessment of teclistamab in relapsed/refractory amyloidosis: a case study
Zhe Chen1, Zhijian Zhang1, Jieni Yu1
1Department of Hematology, Shaoxing People's Hospital, Shaoxing, China.
Abstract:
Systemic light chain amyloidosis (AL) is an uncommon disorder of clonal plasma cells, marked by the creation of amyloid-forming immunoglobulin light chains that result in amyloid fibril formation and deposition, causing dysfunction in multiple organs. There is no established treatment protocol for patients with relapsed or refractory AL. Teclistamab is a bispecific antibody targeting B-cell maturation antigen (BCMA) and is approved for treating relapsed or refractory multiple myeloma (MM). The objective of our study was to report real-world data on the safety and efficacy of teclistamab in patients with relapsed/refractory AL.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Therapeutic Drug Monitoring: Affecting Factors
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions